Oxaliplatin

For research use only.

Catalog No.S1224 Synonyms: L-OHP

84 publications

Oxaliplatin Chemical Structure

CAS No. 61825-94-3

Oxaliplatin (L-OHP) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Oxaliplatin has been cited by 84 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin (L-OHP) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.
Features This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[9]
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HKESC-2 NV\hZ5FGS3m2b4TvfIlkcXS7IFHzd4F6 MljJNQKBmzF4MNMg{txO NIXKXWw1QMLiaB?= NUW2fJdVUUN3ME21MljDqMLzwrCwMlUh|ryP NWPRTGRyOjZ2N{S2PVM>
CaES-17 MofBR5l1d3SxeHnjbZR6KEG|c3H5 NUDHW5c2OOLCk{G2NOKh|ryP M{DZUVQ5yqCq Mlz0TWM2OD13LkZCpOKyyqByLkKg{txO M{XjSlI3PDd2Nkmz
SW480 NUPjXFJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDBOFghcMLi MVzJR|UxRTFwOEeg{txO M4SzdVI3OjZ7N{W5
HCT116 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDyZVJPPDhiaNMg Ml64TWM2OD1zMT64OkDPxE1? NGjxd3czPjJ4OUe1PS=>
LoVo MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWW0PEBpyqB? MXjJR|UxRTl2LkizJO69VQ>? Mn\VNlYzPjl5NUm=
SK-BR-3 M3H5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTNzLkCgxtEhOC5zIN88US=> NUWybJI3OjZ{MUG1PVE>
MCF-7 M1O2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDzWm9bUUN3ME2xOU41KMLzIECuN{DPxE1? NEHGSm8zPjJzMUW5NS=>
MDA-MB-231 M13Ibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zEdWlEPTB;MkOuNUDDuSByLkGg{txO MYCyOlIyOTV7MR?=
HCT116 p53+/+ NXq3NHgyTnWwY4Tpc44hSXO|YYm= MVqxM|Uh|ryP M{DqdlI1NzR6IHi= MofIbY5lfWOnczD0doFve2O{aYD0bY9v[WxicnXwdoV{e2mxbjDv[kBFXVRvTh?= MlywNlYzODh3MkO=
LoVo  MVnGeY5kfGmxbjDBd5NigQ>? NFizOm8yNzVizszN MXGyOE81QCCq NIO1e2xqdmS3Y3XzJJRz[W6|Y4LpdJRqd26jbDDy[ZBz\XO|aX;uJI9nKESXVD3O MmHMNlYzODh3MkO=
SNU-398 NYC4WJJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmeyTWM2OD14LkZCpOKyyqBzLkGg{txO M3HZNVI3OTZyNEK5
Hep-G2 NV73eYtET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PlV2lEPTB;MUOuNeKhyrIEoEGuOkDPxE1? NWH0bmM{OjZzNkC0Nlk>
SNU-475 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnFOnRoUUN3MP-8olMxKM7:TR?= M4i2N|I3OTZyNEK5
SNU-387 NUHN[VVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJ3wrFCteKhOi55IN88US=> MljJNlYyPjB2Mkm=
HT29 NGK3bJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLGWo1KSzVyPUCuPFjDqMLzwrCwMlIh|ryP NGr0PWQzPjF2OEW5Oi=>
HCT116 NF;US5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrJTWM2OD1yLkSxxsDDucLiMD6wNkDPxE1? M1\6W|I3OTR6NUm2
PA-1 NH;UWZBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFTiTlMxNTJyIN88US=> NF;xeGwzPC92ODDo NH7U[ZVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M3nCW|I3OTN6Nkex
OVCAR-5 Mo\xR4VtdCCYaXHibYxqfHliQYPzZZk> NFfUdnAxNTZyIN88US=> NXPDR|V[OjRxNEivO|IhcA>? MnnsbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= Mny1NlYyOzh4N{G=
SK-OV-3 NGjLcJRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{fpWVAuOTByIN88US=> MnfwNlQwPDhxN{KgbC=> NHm4OHRqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NFO4bIYzPjF|OE[3NS=>
PA-1 M1HvXmZ2dmO2aX;uJGF{e2G7 MVGxNEDPxE4EoB?= NGHNOZczPGh? MmDIeJJq\2encnXzJJRp\SCycn;keYN1cW:wIH;mJJR6eGViSTDJSm5{KGGwZDDjbIVud2urbnXz MXKyOlE{QDZ5MR?=
OVCAR-5 M{KxW2Z2dmO2aX;uJGF{e2G7 M1nMSlMxKM7:TR?= Mo[0OFhp MWL0dolo\2W{ZYOgeIhmKHC{b3T1Z5Rqd25ib3[geJlx\SCLIFnGUpMh[W6mIHPo[Y1wc2mwZYO= NYTuZoNnOjZzM{i2O|E>
SK-OV-3 Ml2ySpVv[3Srb36gRZN{[Xl? NGfXdJM2OCEQvF2= NUXPXnNbQTZiaB?= MlzVeJJq\2encnXzJJRp\SCycn;keYN1cW:wIH;mJJR6eGViSTDJSm5{KGGwZDDjbIVud2urbnXz NF7PeHEzPjF|OE[3NS=>
PA-1 NFT3OXdHfW6ldHnvckBCe3OjeR?= MmDUNVAh|ryPwrC= MXi0PIg> MWj1dE1z\We3bHH0[ZMhfGinIIP0doV{eyCuaXfhcoR{KG[xcjDOT{Bk\WyuLXHjeIl3[XSrbnegdoVk\XC2b4LzJIFv\CCWUlHJUEBz\WOncITvdpM> MYKyOlE{QDZ5MR?=
OVCAR-5 MX;GeY5kfGmxbjDBd5NigQ>? NHfFVGo{OCEQvF2= MWW0PIg> NVHPU2p[fXBvcnXneYxifGW|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K| NF\tR5IzPjF|OE[3NS=>
SK-OV-3 NYLDVGFRTnWwY4Tpc44hSXO|YYm= NILBd|k2OCEQvF2= MXO5OkBp MUX1dE1z\We3bHH0[ZMhfGinIIP0doV{eyCuaXfhcoR{KG[xcjDOT{Bk\WyuLXHjeIl3[XSrbnegdoVk\XC2b4LzJIFv\CCWUlHJUEBz\WOncITvdpM> MYSyOlE{QDZ5MR?=
PA-1 MlvrSpVv[3Srb36gRZN{[Xl? MWexNEDPxE4EoB?= MkPYNlRp M2rvfZBzd22xdHXzJJNmdnOrdHn2bZR6KG:oIH;2ZZJq[W5iY3HyZ4lvd22jIITvJG5MKGOnbHytcYVlcWG2ZXSgZ5l1d2y7c3nz MVuyOlE{QDZ5MR?=
OVCAR-5 NFrhNYlHfW6ldHnvckBCe3OjeR?= M1PrXlIxKM7:TdMg M{K3VlI1cA>? NGnNT2txem:vb4Tld{B{\W6|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=> NYjNdo9YOjZzM{i2O|E>
SK-OV-3 M2\jW2Z2dmO2aX;uJGF{e2G7 NHLUcmk2OCEQvF5CpC=> MV[0PEBpyqB? NVXofmVNeHKxbX;0[ZMhe2Wwc3n0bZZqfHlib3[gc5ZiemmjbjDjZZJkcW6xbXGgeI8hVktiY3XscE1u\WSrYYTl[EBkgXSxbInzbZM> MmDqNlYyOzh4N{G=
CT26  M2PnZmZ2dmO2aX;uJGF{e2G7 NVPkfWJUPCCvTR?= MnmxOFghcMLi M3jRNIlv\HWlZYOgZZV1d3CqYXf5 MWWyOlE{PzBzMh?=
CT26  MXLGeY5kfGmxbjDBd5NigQ>? NX7JcmpIPCCvTR?= MWO0PEBpyqB? MXfpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Yx{KG:oIHH1eI9xcGGpeT3y[YxifGWmIIDyc5RmcW6|LDDzeYNpKGG|IFzDN{1KUSxiQnXjcIlvOSCjbnSgRXRIPQ>? M3;DR|I3OTN5MEGy
CT26  NUjVPZR{S2WubDDWbYFjcWyrdImgRZN{[Xl? NWS5NoVPPCCvTR?= MlnoOFghcMLi NHHwRWhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgeI8hPTNwMjW= NEnheVMzPjF|N{CxNi=>
BE NWLuZVF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG3[JVKSzVyPUOuN|Mh|ryP MoG1NlYxOjNyOEW=
Colo205 NUPmdlloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTNwM{Og{txO NED4cIYzPjB{M{C4OS=>
DLD1 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PqOmlEPTB;Mj6wNUDPxE1? NVz6fndxOjZyMkOwPFU>
HT29 NVj2bFV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33t[mlEPTB;Mj62PUDPxE1? M36yNlI3ODJ|MEi1
HCT15 NUHURYNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfkdnVKSzVyPUGuOFMh|ryP MlPZNlYxOjNyOEW=
HCT116 M3Lo[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFwMESg{txO Mo\kNlYxOjNyOEW=
HCT116p53- NH24eopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlntTWM2OD1zLkC4JO69VQ>? M1n5[|I3ODJ|MEi1
KM12 MkTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLDOWNYUUN3ME20MlM4KM7:TR?= NX;keJh4OjZyMkOwPFU>
LoVo NInue2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DwO2lEPTB;MT6yJO69VQ>? NHPsS3YzPjB{M{C4OS=>
RKO NUW0WGROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFwMkOg{txO NUXreJRDOjZyMkOwPFU>
SW480 NYf2U3JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJwOE[g{txO NH\vR5YzPjB{M{C4OS=>
SW620 MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPUeo03UUN3ME2zMlY5KM7:TR?= NEnCUoYzPjB{M{C4OS=>
MC38 NIP6dpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPPb3RMUUN3ME2yN{DPxE1iwsGgNi=> NEHRVnAzPjByNEC4OC=>
HT29 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrQNpVxUUN3ME22N{DPxE1iwsGgNVg> NFvxNIUzPjByNEC4OC=>
DLD-1 MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTN{LkKg{txO NVqxdHA{OjZyMEOwPFU>
HT-29 NFPFOWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj3fYVKSzVyPUO1MlYh|ryP NUn6O5R7OjZyMEOwPFU>
SiHa M{HNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vSS2lEPTB;MD64JOKyKDBwMTFOwG0> NWjocIt1OjV6MEGwNFc>
S3 NGrXdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDjbmFKSzVyPUWzMlUhyrFiMT61JO69VQ>? MWGyOVgxOTByNx?=
AGS M4rnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonxTWM2OD1zMD62JO69VQ>? NXOyc4FtOjV5OEmwOVc>
MKN-45 NGr6NndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLlPWd4UUN3ME2xOE4xKM7:TR?= MVmyOVc5QTB3Nx?=
TMK-1 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrvelI2UUN3ME2yNk43KM7:TR?= NHHCcY4zPTd6OUC1Oy=>
SCM-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjFTJI5UUN3ME2xO{42KM7:TR?= M2HhcVI2Pzh7MEW3
HCT-15 NX3DWHZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvHcXVJUUN3ME24MlY1KM7:TR?= M1HRO|I2PzZzNEe5
DiFi M3H5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnxbZlKSzVyPUGwMlk2KM7:TR?= MVqyOVc3OTR5OR?=
DLD-1 MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRThwNkWg{txO NUHaU5BOOjV5NkG0O|k>
COLO-320DM M{XxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjOb4J{UUN3ME21MlM5KM7:TR?= MUiyOVc3OTR5OR?=
SNU-175 M4LYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFwNUGg{txO MXqyOVc3OTR5OR?=
HT-29 NIj2N3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;nWnZKSzVyPUWuNlIh|ryP NEfaNYYzPTd4MUS3PS=>
SW620 MWXGeY5kfGmxbjDBd5NigQ>? MnH1NVDjiIoEtXevcYw> NFTaZWczPOLCiXi= NWDiV2dPcW6lcnXhd4V{KEyFMz3JTUBi[2O3bYXsZZRqd25iYX7kJIRm[3KnYYPld{BRPjJiZYjwdoV{e2mxbh?= M1j5ZVI2PzR7NEKw
SW480 Mo\ZSpVv[3Srb36gRZN{[Xl? NH\YeFgyOOLCidM1[{9udA>? MkG3NlTjiImq NHrXR4ZqdmO{ZXHz[ZMhVEN|LVnJJIFk[3WvdXzheIlwdiCjbnSg[IVkemWjc3XzJHA3OiCneIDy[ZN{cW:w NHLQUpczPTd2OUSyNC=>
SW620 MWPGeY5kfGmxbjDBd5NigQ>? Mo\FNVDjiIoEtXevcYw> NX\NZVBJOjUkgJno M13WNoVvcGGwY3XzJINmdGy3bHHyJIF2fG:yaHHnbYMh\my3eB?= NFLySFYzPTd2OUSyNC=>
SW480 MmTXSpVv[3Srb36gRZN{[Xl? MnvmNVDjiIoEtXevcYw> M33RTFI16oDLaB?= M3W1ZoVvcGGwY3XzJINmdGy3bHHyJIF2fG:yaHHnbYMh\my3eB?= NF72eokzPTd2OUSyNC=>
A549 NIHL[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfJTWM2OD13LkigxtEhOC54IN88US=> M1XRbFI2PjJ3MkSz
A549/CDDP NIK3WZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HpWmlEPTB;MUiuOkDDuSBzLkKg{txO MlLHNlU3OjV{NEO=
Panc-1 NXPvPWJDS2WubDDWbYFjcWyrdImgRZN{[Xl? NYW1eW5WOjVxNUCg{txO NITUU24zPC92ODDo NIP0NGVqdmirYnn0d{Bxem:uaX\ldoF1cW:wIH;mJHBEKGOnbHzzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? NFnuWGszPTR2NEmxOC=>
MIAPaCa-2 NUTrZ2V1S2WubDDWbYFjcWyrdImgRZN{[Xl? M4LFU|I2NzVyIN88US=> M3POOFI1NzR6IHi= M1LqeYlvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? NH3OPWEzPTR2NEmxOC=>
SW1990 Mmr2R4VtdCCYaXHibYxqfHliQYPzZZk> MofhNlUwPTBizszN MVeyOE81QCCq NH\mPZFqdmirYnn0d{Bxem:uaX\ldoF1cW:wIH;mJHBEKGOnbHzzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? M3rkOFI2PDR2OUG0
HPDE M13YcGNmdGxiVnnhZoltcXS7IFHzd4F6 NHXBOXczPS93MDFOwG0> M1ey[VI1NzR6IHi= MXfpcohq[mm2czDwdo9tcW[ncnH0bY9vKG:oIGDDJINmdGy|IHnuJIEhe3mwZYLnbZN1cWNibXHucoVzKGOxbXLpcoVlKHerdHigW2E> Mn3iNlU1PDR7MUS=
Panc-1 MWTBdI9xfG:|aYOgRZN{[Xl? MVeyOgKBkcL3TR?= NGDYW|gzPCCq MXLpcoR2[2W|IHHwc5B1d3OrczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MVGyOVQ1PDlzNB?=
MIAPaCa-2 MkfuRZBweHSxc3nzJGF{e2G7 NHX5WVkzPeLCidM1US=> MmKxNlQhcA>? NWW5b3V6cW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?= MkK3NlU1PDR7MUS=
Panc-1 M1vRU2Z2dmO2aX;uJGF{e2G7 M3\nS|I26oDLwsXN MlPSNlQwPDhiaB?= M4GxfYlv\HWlZYOgZ4xm[X[jZ3Wgc4YhWEGUUDygZ4F{eGG|ZT25MEBk[XOyYYPlMVgh[W6mIHPhd5Bie2VvM9Mg NUG0OWpTOjV2NES5NVQ>
MIAPaCa-2 M3T3ZWZ2dmO2aX;uJGF{e2G7 NYHE[XNSOjYkgJpCuW0> NEK1eXQzPC92ODDo NIG0ZmpqdmS3Y3XzJINt\WG4YXflJI9nKFCDUmCsJINie3Cjc3WtPUwh[2G|cHHz[U05KGGwZDDjZZNx[XOnLURCpC=> M3\iOFI2PDR2OUG0
SW480 Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTPfJhSPzJiaNMg MkS4TWM2OD1zMD63xtEzNjJ4INM1[{9uVA>? NX6ydnZvOjV|NkC2N|E>
HCT116  MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\4RlY1PzJiaNMg MkewTWM2OD14LkKzxtExNjd3INM1[{9uVA>? MlnyNlU{PjB4M{G=
COC1 M13LXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjQ[VlKSzVyPUS2MlIxyqEEsdMgN{4yPCEQvF2= MXOyOVMxPzR2OB?=
SGC7901 NVP1XZZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH2TWpKSzVyPUKxMlc{yqEEsdMgN{4xQCEQvF2= NF;Cc5YzPTNyN{S0PC=>
A549 NEXZSJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3qVpdKSzVyPUWxMlA5yqEEsdMgNVAvQTZizszN NGDp[4UzPTNyN{S0PC=>
HepG2 NY[wdJpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS4TWM2OD1zND6yOOKhyrIEoEGuPFIh|ryP M1m5fVI2OzB5NES4
MCF-7 NYHr[GtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHmzNo9KSzVyPUG0MlI1yqEEsdMgNU45OiEQvF2= NEfuRWUzPTNyN{S0PC=>
HCT-116 NXfFcJF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTZwMkVCpOKyyqB{Lkm3JO69VQ>? NV\LR2F7OjV|MEe0OFg>
HT-29 MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXCXVV[UUN3ME61NEDPxE1? NFzhUFYzPTNyN{S0PC=>
HEK293 NU\RNlVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPjTWM2OD16LkiyxsDDucLiNT61PUDPxE1? M1fudlI2OzB5NES4
HUVEC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTqTWM2OD1zMT6zNOKhyrIEoEGuNFIh|ryP Ml\2NlU{ODd2NEi=
SW480 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXzb3NpOcLizszN NUjINnRNOC15MjDo NVH1Z2hucW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? NYLsT2hPOjR7OUe0OVE>
HT-29 NHu4[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT2NeKh|ryP NV3CVpZSOC15MjDo MnnmbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MUKyOFk6PzR3MR?=
HCT116 NWfsPYlmTnWwY4Tpc44hSXO|YYm= MVyyM|UhyrWP MXyyOE81QCCq MnzId5VxeHKnc4Pld{B{fXK4aY\pckBuWk6DIHX4dJJme3Orb36= MUWyOFc3OTRzMR?=
SW480  MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfMOFghcMLi M2nKXWlEPTB;MkCuPEB2\y:vTB?= NHzPeIEzPDd{ME[3OS=>
SW620 NE\SdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjMWJd3OTBvN{CgcYcwVA>? NXjTcnNCOjRxNEivO|IhcA>? MlPLbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MY[yOFY1PjNyNR?=
Caco2  NImwN3hHfW6ldHnvckBCe3OjeR?= NWXqRVUyOzEEoN88US=> NFXwT|czPCCq NX;PXWJXTE2VTx?= MWDpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFjPMVEtKEGNUkHDMEBidmRiTmHPNS=> M{\P[lI1PTV4NEG1
Caco2  MUnGeY5kfGmxbjDBd5NigQ>? NFOxd2g{NzFyL{OwJO69VQ>? MUGxOkBp NH\LemZFVVOR M4Ltbolv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqEGNUkHDNUwhVlGRMTygTG8uOSxiTWLQNkzDqGGwZF3SVFPDqGSxc3Wt[IVx\W6mZX70cJk> MnvuNlQ2PTZ2MUW=
Caco2 NYfHNFBSTnWwY4Tpc44hSXO|YYm= MmrFN|AwOTBywrFOwG0> M13GS|E3yqCq NXzWWplmTE2VTx?= NFfReXZi[3SrdnH0[ZMhVnKoMh?= M4PRV|I1PTV4NEG1

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
VEGFR-1 / NRP-1 ; 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin (0.2 and 2 μmol/L) in 1% MEM-FBS. Western blotting analysis showed that oxaliplatin treatment up-regulated VEGFR-1 and NRP-1 protein expression. 

p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416); 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin for 5, 15, 30, and 60 min. Western blotting showed that oxaliplatin induced Akt activation, with peak phosphorylation occurring at 60 min and decreased PTEN. Phospho-Src increased at 30 min.

p-Src(Y418) / p-FAK(Y861) ; 

PubMed: 19383922     


Src and FAK activation by Western blots were determined at various time periods after oxaliplatin treatment (2.5 µM) for HT29 and KM12-L4 cells, and representative of triplicate experiments. Densitometry represents a ratio of the phosphorylated form to th䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ

18790786 19383922
Immunofluorescence
E-cadherin / Vimentin; 

PubMed: 30787271     


Silencing ATXN2L reversed oxaliplatin-induced epithelial mesenchymal transition in MGC803 cells.

ATXN2L / G3BP1; 

PubMed: 30787271     


Under different concentrations and durations of oxaliplatin stimulation, the immunfluorescence staining expressions of ATXN2L and G3BP1 were enhanced by different levels, and ATXN2L coexpressed with G3BP1 in stress granules. 

30787271
Growth inhibition assay
Cell viability ; 

PubMed: 28339092     


Cell viability curve of BGC-823 and MKN-28 cells treated with oxaliplatin at different concentrations. 

28339092
In vivo

A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:

[4]

- Collapse
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method:

    The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control


    (Only for Reference)
Animal Research:

[6]

- Collapse
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
DMF Insoluble
Ethanol ''''0.01 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% glucose (with warming)
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage 2 years 4°C(in the dark) powder
1 week 4°C(in the dark) in solvent
Synonyms L-OHP
Smiles C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04158349 Recruiting Drug: Oxaliplatin|Drug: mFOLFIRI Colorectal Cancer|Appendiceal Cancer|Peritoneal Carcinoma University of Utah June 11 2020 Phase 1
NCT04003792 Not yet recruiting Drug: oxaliplatin|Drug: FOLFIRI Protocol|Drug: Bevacizumab Liver Metastasis Colon Cancer Rabin Medical Center January 2020 Phase 2
NCT04261920 Recruiting Drug: Huangqi Guizhi Wuwu decoction Oncology Jiangsu Famous Medical Technology Co. Ltd. January 3 2020 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Oxaliplatin | Oxaliplatin supplier | purchase Oxaliplatin | Oxaliplatin cost | Oxaliplatin manufacturer | order Oxaliplatin | Oxaliplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID